Conjugation of Triphenylphosphonium Cation to Hydrophobic Moieties to Prepare Mitochondria-Targeting Nanocarriers
- 31 May 2019
- book chapter
- Published by Springer Nature
- Vol. 2000, 183-189
Abstract
The contribution of mitochondrial dysfunctions to diseases such as cancer, diabetes, cardiovascular, and neurodegenerative diseases has made mitochondria an attractive pharmacological target. To deliver biologically active molecules to mitochondria, however, cellular and mitochondrial barriers must be first overcome. The mitochondrial transmembrane electric potential (negative inside) is among the most commonly used strategies to deliver molecules to mitochondria as it allows the accumulation of positively charged molecules. Thus, therapeutic molecules are either covalently conjugated to lipophilic cations like triphenylphosphonium (TPP) or loaded into nanocarriers conjugated to TPP.Keywords
This publication has 22 references indexed in Scilit:
- Mitochondria as a pharmacological target: Magnum overviewIUBMB Life, 2013
- Surface conjugation of triphenylphosphonium to target poly(amidoamine) dendrimers to mitochondriaBiomaterials, 2012
- Mitochondrial pharmacologyTrends in Pharmacological Sciences, 2012
- Targeting mitochondria for cancer therapyNature Reviews Drug Discovery, 2010
- Targeting lipophilic cations to mitochondriaBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2008
- Mitochondriotropic LiposomesJournal of Liposome Research, 2005
- Mitochondria as a Pharmacological TargetPharmacological Reviews, 2002
- Development of lipophilic cations as therapies for disorders due to mitochondrial dysfunctionExpert Opinion on Biological Therapy, 2001
- Selective targeting of bioactive compounds to mitochondriaTrends in Biotechnology, 1997
- Mechanism of Coupling of Oxidative Phosphorylation and the Membrane Potential of MitochondriaNature, 1969